Literature DB >> 8785466

ACE inhibitors in elderly patients with hypertension. Special considerations.

M Ravid1, D Ravid.   

Abstract

Angiotensin converting enzyme (ACE) inhibitors have emerged as the class of antihypertensive and vasodilatatory agents of first choice in the treatment of elderly patients with hypertension. Normotensive patients with congestive heart failure, post-anterior myocardial infarction, or diabetes mellitus with evidence of microangiopathy will also benefit from continuous ACE inhibition. The long term use of ACE inhibitors is associated with improved survival and reduced cardiovascular, cerebral and renal morbidity in these patients. In elderly atherosclerotic patients, these agents provide good control of systolic and diastolic blood pressure and peripheral resistance, with remarkable preservation of vital organ perfusion and infrequent adverse effects. Used as monotherapy, the effectiveness of ACE inhibitors is limited. However, there are advantages for using them in combination with other drugs, notably thiazide diuretics, nitrates and calcium antagonists. Renal function is thus preserved and left heart hypertrophy is prevented. There are no major differences between the various ACE inhibitors, and the choice of drug is largely a matter of personal preference.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8785466     DOI: 10.2165/00002512-199608010-00006

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  87 in total

1.  ACE inhibition improves insulin-sensitivity in aged insulin-resistant hypertensive patients.

Authors:  G Paolisso; A Gambardella; M Verza; A D'Amore; S Sgambato; M Varricchio
Journal:  J Hum Hypertens       Date:  1992-06       Impact factor: 3.012

2.  Essential hypertension in the elderly: haemodynamics, intravascular volume, plasma renin activity, and circulating catecholamine levels.

Authors:  F H Messerli; K Sundgaard-Riise; H O Ventura; F G Dunn; L B Glade; E D Frohlich
Journal:  Lancet       Date:  1983-10-29       Impact factor: 79.321

3.  Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators.

Authors:  M A Konstam; M F Rousseau; M W Kronenberg; J E Udelson; J Melin; D Stewart; N Dolan; T R Edens; S Ahn; D Kinan
Journal:  Circulation       Date:  1992-08       Impact factor: 29.690

Review 4.  Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology.

Authors:  Z H Israili; W D Hall
Journal:  Ann Intern Med       Date:  1992-08-01       Impact factor: 25.391

5.  Efficacy and safety of lisinopril in older patients with essential hypertension.

Authors:  H J Gomez; S G Smith; F Moncloa
Journal:  Am J Med       Date:  1988-09-23       Impact factor: 4.965

6.  Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs.

Authors:  D W Cushman; F L Wang; W C Fung; C M Harvey; J M DeForrest
Journal:  Am J Hypertens       Date:  1989-04       Impact factor: 2.689

7.  Plasma lipids and the progression of nephropathy in diabetes mellitus type II: effect of ACE inhibitors.

Authors:  M Ravid; L Neumann; M Lishner
Journal:  Kidney Int       Date:  1995-03       Impact factor: 10.612

Review 8.  Differences in structure of angiotensin-converting enzyme inhibitors might predict differences in action.

Authors:  A G Herman
Journal:  Am J Cardiol       Date:  1992-10-08       Impact factor: 2.778

9.  Effect of nifedipine and captopril on glomerular hyperfiltration in normotensive man.

Authors:  J Böhler; R Woitas; E Keller; P Reetze-Bonorden; P J Schollmeyer
Journal:  Am J Kidney Dis       Date:  1992-08       Impact factor: 8.860

10.  Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy.

Authors:  C E Mogensen
Journal:  Br Med J (Clin Res Ed)       Date:  1982-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.